Tuesday, November 21, 2017
 
 
News: Page (1) of 1 - 08/02/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Bristol-Myers suspends hepatitis C treatment study
Bristol-Myers suspends hepatitis C treatment study, cites patient safety problem
By The Associated Press

NEW YORK (AP) Drugmaker Bristol-Myers Squibb says it is suspending a mid-stage study of a potential hepatitis C treatment due to a serious patient safety issue.

The New York company did not elaborate on the problem in a brief statement. It says the cause of the issue and potential relationship to the drug are unknown.

Bristol-Myers shares are down more than 5 percent in premarket trading Thursday.



The drug company is making a push to become a player in the hepatitis C drug market, and it acquired the potential treatment as part of a $2.5 billion acquisition of drug developer Inhibitex that closed earlier this year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts say the market for treatments is potentially lucrative for drugmakers.


Page: 1


 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines